Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas.

Literature DB >> 15273141

In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas.

S Pereyre¹, H Renaudin, C Bébéar, C M Bébéar.

Abstract

The activities of garenoxacin, gatifloxacin, and gemifloxacin were compared with those of four fluoroquinolones against human mycoplasmas and ureaplasmas, including fluoroquinolone-resistant genetically characterized strains. Garenoxacin exhibited the highest activity, followed by gemifloxacin, moxifloxacin, and gatifloxacin. The minimal bactericidal activities of these three compounds were lower than those of the four fluoroquinolones.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2004 PMID： 15273141 PMCID： PMC478505 DOI： 10.1128/AAC.48.8.3165-3168.2004

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

15 in total

1. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756.

Authors: J C Fung-Tomc; B Minassian; B Kolek; E Huczko; L Aleksunes; T Stickle; T Washo; E Gradelski; L Valera; D P Bonner
Journal: Antimicrob Agents Chemother Date: 2000-12 Impact factor: 5.191

2. Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp.

Authors: L B Duffy; D Crabb; K Searcey; M C Kempf
Journal: J Antimicrob Chemother Date: 2000-04 Impact factor: 5.790

Review 3. Review of the in vitro activity of gemifloxacin against gram-positive and gram-negative anaerobic pathogens.

Authors: E J Goldstein
Journal: J Antimicrob Chemother Date: 2000-04 Impact factor: 5.790

4. Comparative in vitro activity of gemifloxacin.

Authors: A King; J May; G French; I Phillips
Journal: J Antimicrob Chemother Date: 2000-04 Impact factor: 5.790

5. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin.

Authors: J Fung-Tomc; B Minassian; B Kolek; T Washo; E Huczko; D Bonner
Journal: J Antimicrob Chemother Date: 2000-04 Impact factor: 5.790

6. The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone.

Authors: R Wise; J M Andrews
Journal: J Antimicrob Chemother Date: 1999-11 Impact factor: 5.790

7. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones.

Authors: G E Kenny; F D Cartwright
Journal: Antimicrob Agents Chemother Date: 2001-09 Impact factor: 5.191

8. Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis.

Authors: C M Bebear; J Renaudin; A Charron; H Renaudin; B de Barbeyrac; T Schaeverbeke; C Bebear
Journal: Antimicrob Agents Chemother Date: 1999-04 Impact factor: 5.191

9. In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.

Authors: Ken B Waites; Donna M Crabb; Xue Bing; Lynn B Duffy
Journal: Antimicrob Agents Chemother Date: 2003-01 Impact factor: 5.191

In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas.

1. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756.

2. Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp.

Review 3. Review of the in vitro activity of gemifloxacin against gram-positive and gram-negative anaerobic pathogens.

4. Comparative in vitro activity of gemifloxacin.

5. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin.

6. The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone.

8. Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis.

9. In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.

10. Inhibitory and bactericidal activities of gemifloxacin and other antimicrobials against Mycoplasma pneumoniae.

1. Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae.

Review 2. Clinical Utility of Lefamulin: If Not Now, When?

Review 3. Gemifloxacin use in the treatment of acute bacterial exacerbation of chronic bronchitis.

Review 4. Mycoplasma pneumoniae: Current Knowledge on Macrolide Resistance and Treatment.